ESMO 2017, 8 - 12 September, 2017
08 September 2017
Showing 1308 posters
7P. GSKJ4, a H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells
9P. Kynurenine-3-monooxygenase (KMO) protein promotes triple negative breast cancer progression
13P. AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression
14P. Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model.
15P. Estrogen-dependent breast cancer: the importance of androgen receptor in exemestane treatment
16P. Phosphatidylinositol 3-kinase (PI3K?)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
18P. Potential miRNAs involved in molecular pathways mediating the anticancer effects of Short Term Starvation in Breast Cancer cells treated with Doxorubicin
19P. An endothelial premetastatic-like niche is promoted by tumor-secreted factors derived from highly metastatic breast cancer cells in vitro.
20P. Selective Accumulation of the Rat Adherent Natural Killer Cells in Mammary Tumor Tissues
21P. Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer
22P. The interplay between TP53 and mevalonate pathway in ovarian cancer
23P. Epigenomic landscape of Breast Cancer in Very Young Women
25P. Breast cancer predisposing germline mutations identified by exome sequencing
26P. Transcriptome deregulation of Breast Cancer in Very Young Women
28P. ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
33P. Isoform-Specific AKT Functions in Pancreatic Adenocarcinoma
ePoster34P. High chemopreventive and therapeutic efficacy of Id1 Inhibition in KRAS-mutant (KM) adenocarcinoma (AD) non-small cell lung cancer (NSCLC)
36P. Synergistic effect of Vismodegib and Cisplatin in NSCLC models via autophagy
38P. Two-step microarray analysis of cell-free miRNA in plasma of lung cancer patients
42P. Preserving tumor heterogeneity: A microfluidic reactor for ex vivo preservation of colorectal cancer biopsies
44P. Role of ICAM-1/LFA-1 interaction in the angiogenic and desmoplasic response in Liver metastasis
45P. Role of discoidin domain receptors in extracellular matrix remodeling during tumor-host interaction in liver metastasis
46P. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells
47P. GATA6 exhibits tumor suppressive effects in hepatocellular carcinoma
48P. The effects of 5-fluorouracil (5-FU) on TGF-β-related signaling molecules
49P. gene mutations involved in drug resistance in liver cancer cells using a new rna-seq data analysis workflow
4PD. GGNBP2 suppresses tumor growth and cancer stem cell load of triple negative breast cancer by controlling STAT3 pathway
ePoster51P. Delivery of paclitaxel-loaded erythrocytes-based nanoparticles using injectable albumin hydrogel for regional chemotherapy
52P. Effect of apatinib combined with 5-fluorouracil (5-FU) on proliferation, apoptosis and invasiveness of gastric cancer cells
53P. One tumour, Two Clones: An in vitro Model of Intra-tumour heterogeneity
54P. Docosahexaenoic acid mediates susceptible cell death through differential regulation of p62/p-eIF2alpha/NRF2 in LMP1-expressing nasopnaryngeal carcinoma cells
56P. Oral squamous cell carcinoma cells were sensitized to cetuximab by Eribulin via induction of the mesenchymal-to-epithelial transition.
57P. In vivo study of the vaccine adjuvants prothymosin alpha and prothymosin alpha(100-109) in melanoma
58P. Melanoma affects clock gene machinery of several organs in tumor-bearing mice
5PD. The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling
60P. Understanding and targeting Met signalling in bladder cancer
61P. Integrated molecular signatures of TERT promoter deregulation predict disease outcomes in non-muscle invasive bladder cancer
62P. Dose- and regimen-dependent effects of dexamethasone on extracellular matrix of brain tissue
63P. Clinical dysregulation of DNA repair by the Polynucleotide Kinase/Phosphatase-XRCC4-DNA Ligase IV protein complex in neurological disease
65P. Influence of emotiogenic brain structures on tumor growth in the experiment
66P. Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumours (NET)
67P. Developing a prediction model for response to lenalidomide treatment in refractory/relapsed multiple myeloma patients
68P. Combinatorial Inhibition of mTOR and Exportin-1 (XPO1) Represses Cell Survival Via Metabolic Modulation of Pro-survival Pathways in Mantle Cell Lymphomas
69P. CD200 and IDO-1 overexpresion in relapsed acute myeloid leukemia patients
6PD. FPA150, a Novel B7-H4 Therapeutic Antibody with Checkpoint Blockade and ADCC Activities
70P. Correlation between types of Acute Lymphoblastic Leukemia with Socio demographic factors
71P. CALR mutations and their link with cellular calcium during megakaryocyte hyperplasia in MPNs
72P. Approach based on magnetic nanocomplexes improves antitumor efficacy of dendritic cells immunotherapy in mice
75P. Signs of tumor-specific immune processes in the regression of large rat tumors under the influence of low-intensity EMR EHF and magnetite nanoparticles
78P. Registration-based automated lesion detection and therapy evaluation of tumors in whole body PET-MR images
81P. A new isoquinoline alkaloid bersavine as a possible anticancer agent
83P. The impact of co-culture of NSCLC tumor cells and fibroblasts on drug response
88P. PALB2 Reversion Mutations in Breast, Prostate, and Ovarian Carcinomas
89P. Pan-cancer genomic analysis of MSI-H tumors reveals commonly altered pathways
90P. molecular feature and clinical use development of gene expression profile "TP53 signature" in early stage breast cancer
91P. Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts)
92P. Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial
93P. Characterization of a Novel Tumor-Suppressor Gene CHL1 at 3p26.3 in Esophageal Squamous Cell Carcinoma
95P. Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients
96P. Predictive biomarkers for adjuvant therapy in gastric adenocarcinoma
97P. Large-scale DNA organization is a prognostic marker of breast cancer survival
100P. Biomarkers of immune therapy in CUP
101P. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
102P. Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST)
103P. Comparison of continuous measures across diagnostic PD-L1 assays using image analysis
104P. Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Novel Carcinoembryonic Antigen (CEA) T-cell Bispecific Antibody (CEA-CD3 TCB) for the Treatment of CEA-Positive Solid Tumors
105P. Baseline gut microbiota in metastatic melanoma patients treated with ipilimumab: relation with clinical response and colitis.
106P. The association between PD-L1 expression, EGFR mutation and ALK translocation in a series of 1,005 lung cancers
107P. Association of tumor and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with response to nivolumab treatment in NSCLC patients
108P. Characterisation of heterogeneity in microsatellite instable (MSI) tumours associated with distinct cell types and immune phenotypes
110P. Prognostic and predictive value of lymphovascular invasion and lymph node status among breast cancer subtypes
111P. PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy?
113P. Can a Systemic Inflammation Response Index (SIRI) predict Overall Survival (OS) in metastatic Pancreatic Cancer (PC)?
114P. Molecular imaging with 18F-Fluoroestradiol (18F-FES) to assess intra-patient heterogeneity in metastatic breast cancer (MBC): a European TRANSCAN program.
115P. Evaluation of a Predictive Radiomics Signature for Response to Immune Checkpoint Inhibitors (ICIs)
118P. Nationwide External Quality Assessment (EQA) of EGFR testing in circulating tumor DNA: the French experience
119P. IL-8 as a Pharmacodynamic biomarker for TGF-?2 antisense (trabedersen) therapy - Results of a Phase II trial
120P. Predictive Assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial
122P. Cell-free (cf)DNA analysis identifies PIK3CA/AKT1 mutations associated with greater PFS improvement from the addition of ipatasertib (IPAT) to paclitaxel (P) in triple-negative breast cancer (TNBC)
123P. Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004
124P. Role of circulating miRNAs as prognostic biomarkers in resected early-stage non-small cell lung cancer
125P. Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes
126P. Single-cell combined mutation and gene expression studies of circulating tumor-associated cells in non-small cell lung cancer
128P. Detection of esophageal cancer patients using Circulating Serum microRNA from the result of comprehensive analysis
130P. EGFR plasma testing in routine practice by real-time PCR in lung cancer patients: experience of 262 patients
131P. Circulating tumor cells as liquid biopsy for castration resistant prostate cancer patients treated with cabazitaxel
134P. Circulating tumour DNA (ctDNA) in the clinical management of patients (pts) with advanced non-small cell lung cancer (NSCLC): A single centre experience
135P. Genome-wide methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol)
136P. Epigenetic biomarkers in breast cancer: preliminary results from H3K27m3 assessment in endocrine-treatment resistance
137P. Bioinformatic estimate of biomarker-positive populations in Genomics-driven trials using Precision Trial Designer (PTD)
138P. Detection of microsatellite instability (MSI) in colorectal cancer samples with the automated Idylla MSI Test
140P. Metabolic Syndrome and Inflammation in Castration Resistant Prostate Cancer (CRPC) patients (pts) treated with Abiraterone (abi) and Enzalutamide (enza)
141P. Ischemic Stroke and Cancer Correlation: A Stroke Unit Experience
144P. Identification of germline mutation using 30-gene sequencing and clinical characteristic of Chinese with hereditary breast cancer
145P. Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT
146P. Predicting response to chemotherapy in gastric cancer patients randomized to docetaxel: a reevaluation of the ITACA-S trial
147P. The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Pancreatic Cancer.
164P. Impact of Lack of Surgery on Outcomes in Elderly Patients with Non-Metastatic Breast Cancer (BC)– A Population Based Study using the SEER 18 Data Base.
166P. Eight-year follow up results of the OTOASOR Trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. A randomized, single centre, phase III, non-inferiority trial
167P. Time to surgery in early breast cancer treated with neoadjuvant chemotherapy
168P. Updated results of the Breast cancer task force phase II study of neoadjuvant weekly carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts).
169P. Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): a multicenter, two stage, phase II trial
171P. Composite index of risk shows that benefit from adjuvant dose dense chemotherapy is not confined to triple negative breast cancer
172P. The Prognostic impact of Chemotherapy Induced Amenorrhea in Women Treated With Early Stage Breast Cancer
173P. Determinants and outcomes associated with delays in adjuvant chemotherapy among breast cancer patients
174P. Adjuvant Chemotherapy in pT1ab Node-Negative Triple Negative Breast Carcinomas: Results of a National Multi-Institutional Retrospective Study
175P. OHERA - A Real World Study of Cardiac Events in >3700 Patients with HER2-positive Early Breast Cancer Treated with Trastuzumab: Final Analysis
176P. Clinical outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study
177P. Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial
178P. Second interim analysis of HerSCin, a German non-interventional study of subcutaneous trastuzumab for HER2-positive early breast cancer in routine clinical practice
179P. Timing of initiation of trastuzumab (T) and long-term outcome of patients (pts) with early-stage (ES) HER2-positive (HER2+) breast cancer (BrCa): impact of neo-adjuvant (NAdj) versus adjuvant (Adj) strategy
180P. Adjuvant endocrine treatment: stop or continue?
181P. Use and effectiveness of adjuvant ovarian function suppression (OFS) in premenopausal women with early breast cancer.
182P. A phase II randomised study of Adjuvant hypo-fractionated radiotherapy with Concurrent vs Sequential Letrozole in post-menopausal women with Hormone receptor positive Breast Cancer: Report of Pulmonary toxicity and cosmetic outcome
183P. Intrinsic tumor features underlying clinical subtype discordance in early breast cancer.
184P. Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: a retrospective study in Spanish population
185P. The first report of multicenter validation study of 95-Gene Classifier, a multi-gene prognostic assay of estrogen receptor positive and node negative breast cancer patients
186P. Breast cancer PAM50 subtypes: correlation between RNA-Seq and multiplexed gene expression platforms
187P. Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score assay and other genomic assays for early breast cancer
188P. The impact of Oncotype DX breast cancer assay results on clinical practice - a UK experience
189P. Enhancing decision-making about adjuvant chemotherapy in ER+, HER2- early breast cancer (EBC) following EndoPredict testing
190P. Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
191P. Pathological Proliferation Score to predict genomic risk categories in Early Stage Breast Cancer
192P. Population sizes of patients with node negative, HR+, HER2- primary breast cancer, using standard and TAILORx 21-gene Recurrence Score cut-off values
ePoster193P. Oncotype DX score, menopausal status and body mass index
194P. Comparisons of tumor-infiltrating lymphocytes and 21-gene recurrence score in ER-positive/HER2-negative breast cancer
195P. The 70-gene signature in node positive breast cancer: 10-year follow-up of the observational RASTER study.
196P. Higher expression of estrogen response genes in the primary tumor is associated with a greater risk for late recurrence in patients with ER+/HER2- breast cancer
197P. Understanding BRCA1 and BRCA2 mutated breast cancer cases in Romania: first report on founder mutations in Romanians
198P. The prevalence of CD146 expression in breast cancer subtypes and its relation to outcome
199P. Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer
200P. Vitamin D as a prognostic factor in triple negative early breast cancer
201P. CDK12 - new breast and ovarian cancer predisposition gene in Tatar population?
202P. Prognostic Value of Master Transcriptional Regulators (MTRs) in Early Stage Breast Cancer
204P. ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure Invasive Lobular breast Carcinoma (ILC): preliminary results of prognostic outliers according to a clinical-pathological model.
205P. The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)
206P. Incidence of permanent alopecia following adjuvant chemotherapy in women with early stage breast cancer.
207P. Significant changes in dietary intake and physical activity after breast cancer diagnosis in a Chinese breast cancer cohort study
208P. Prevention of Cardiotoxicity in Breast Cancer Patients: A Randomized Prospective Study
209P. Quality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax®) in the preoperative treatment of women with primary breast cancer (ABCSG-34)
218P. Prognostic estimates of Ki-67 percentage drop after neoadjuvant chemotherapy (NAC) in luminal B (lumB) and triple negative breast cancer (TNBC)
219P. Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
220P. Safe resection margins in breast-conserving surgery
221P. A clinically applicable model to predict risk of relapse in patients treated for locally advanced breast cancer. Potential utilization in future clinical trials.
222P. Role of radiotherapy and its impact on survival of male breast cancer: Experience from a tertiary cancer center
224P. Synchronous and Metachronous Breast Cancer in Ukraine
225P. Clinical outcomes of single versus double hormone receptor positive breast cancer patients treated with neoadjuvant chemotherapy
226P. The correlation between toll-like receptor genes polymorphisms, tumor microenvironment characteristics and the effectiveness of preoperative chemotherapy for locally advanced breast cancer
227P. Triple Negative Breast Cancer: 10-year Survival Update of The Applied Treatment Strategy in Kuwait
228P. A decade of HER2-targeted therapy in older patients with invasive breast cancer at Institut Curie
229P. Dedicated breast PET to predict pathological complete response after neoadjuvant chemotherapy for breast cancer.
232P. Pregnancy associated breast cancer spotlights
248P. Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): a PALOMA-2 subgroup analysis
249P. Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease
251P. Efficacy and safety of olaparib combined with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: the final analysis of a Japanese phase I/II trial.
252P. Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
253P. Abemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2
254P. Matching-adjusted indirect treatment comparison of ribociclib and palbociclib as first-line treatments for HR+, HER2– ABC
256P. Efficacy of palbociclib plus fulvestrant in advanced HR+ Metastatic Breast Cancer pretreated with everolimus: Real-life data from the French Temporary Authorization for Use (TAU) at the Institut de Cancérologie de l’Ouest
257P. A phase 1 study of BYL719, an a-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies
258P. Phase 1 study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68, which prevents ?-catenin Translocation in Advanced Solid Tumorsv
259P. Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts) - Preliminary results of the GIM 13 - AMBRA Study
261P. Is PFS a more relevant endpoint than OS in 1L HR+, HER2– MBC? A systematic literature review
262P. PFS/TTP as a potential surrogate for OS in HR+, HER2– MBC
263P. Survival Gains from Advances in First-Line Systemic Therapy for HER2-Positive Metastatic Breast Cancer in the U.S., 1995-2015
265P. Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study
266P. Use of Everolimus in Advanced hormone receptor positive metastatic breast cancer in a multicenter national observational study
267P. Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?
269P. Outcomes of systemic therapy for advanced triple-negative breast cancer: a single centre experience.
270P. Untreated hormone receptor positive / HER2-negative metastatic breast cancer survival with front-line chemotherapy and maintenance endocrine therapy
271P. Can We Predict Subsequent Brain Metastasis in Patients with Metastatic Breast Cancer?
272P. Pathological characteristics and prognosis of a cohort of 57 patients (pts) with de novo oligometastatic breast cancer (OMBC)
273P. External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases
274P. Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry
275P. First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry
276P. Defining Priorities for Research: Interim Results of the Canadian Metastatic Breast Cancer Priority Setting Partnership
277P. Real-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States
279P. Real-World Everolimus Experience in Postmenopausal HR+ HER2- Advanced Breast Cancer Women - Treat ER+ight Canadian Prospective Observational Study 2nd Subgroup Analysis
280P. FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/ HER2- negative metastatic breast cancer patients (MBC) ?45 years old. A large observational multicenter cohort survival analysis.
282P. Gene alteration in triple negative breast cancer patients in a phase I/II study of combination therapy with eribulin and olaparib.
283P. Neutrophil-lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer
284P. Real-life study of BRCA genetic screening in metastatic breast cancer
286P. Holistic therapeutic strategy of TNBC necessitates in depth molecular classification: a prospective study
287P. Neutrophil-to-lymphocyte ratio in metastatic breast cancer: association with clinico-pathological features and outcome.
288P. Prognosis after loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm cancer register.
289P. The CAN BEAR study: a systematic review and meta-analysis investigating adverse events (AEs) of targeted agents added to endocrine therapy (ET) in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC)
290P. OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice (TPC)
291P. PALOMA-2: Neutropenia (NP) Patterns in Patients (Pts) With Estrogen Receptor?Positive (ER+)/Human Epidermal Growth Factor Receptor 2?Negative (HER2–) First-Line Advanced Breast Cancer (ABC) Receiving Palbociclib + Letrozole (P+L)
292P. Prospective observational study of peripheral neuropathy in breast cancer patients treated with eribulin
293P. Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventional study NABUCCO
294P. Assessment of gastric pH changes and food intake on ribociclib bioavailability: in silico and clinical evaluations
295P. Pneumocystis jiroveci pneumonia (PCP) in patients receiving weekly chemotherapy for metastatic breast cancer
296P. Detection of early cardiac effects of Docetaxel Plus Trastuzumab and Pertuzumab through strain rate imaging in Patients with HER2-Positive Metastatic Breast Cancer
298P. Outcomes of intracranial stereotactic radiotherapy (SRT) in metastatic breast cancer (BC)
299P. Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort
300P. Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial)
301P. Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): old drugs, new opportunities Preliminary results of the VICTOR-6 study
302P. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis
303P. Durable Complete Response in HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis
304P. Characterization of breast cancer responses to metformin
306P. All oral combination of Vinorelbine and Capecitabine as a first line treatment in patients (pts) with metastatic breast cancer (MBC)
307P. Retrospective Observational Study to Evaluate the Use of Halaven plus Trastuzumab for the Treatment of HER2(+) Metastatic Breast Cancer (MBC) in Spain. HALATRUST Study
308P. Lower response to T-DM1 in metastatic breast cancer patients with HER2 IHC score of 2 and FISH positive compared with IHC score of 3
309P. Nab-Paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): from randomized trials to real-life setting. Results from GIM13 - AMBRA study
310P. Everolimus-Exemestane (EE) vs Palbociclib-Letrozole (PL) or Palbociclib-Fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. An indirect comparison with network meta-analysis.
337P. Molecular subtypes of gliomas defined by gene expression profiling
338P. Chitosan-capped gold nanoparticles impair radioresistant glioblastoma stem-like cells
339P. Hypoxia, Inflammation and redox status as determinants of malignant progression of cancer stem cells
340P. The Prognostic Role Of High Mobility Group Box Protein-1 In Glioblastoma And Its Relationship With The Inflammatory Response
343P. The role of clinical characteristics in low grade gliomas in molecular era
344P. IDH wild type low grade gliomas: who seeks shall find
345P. Effect of ADM alone or combined with monoclonal anti-programmed death ligand-1 antibody on Glioma cell lineU251 and T lymphocytes
346P. Prognostic Impact of neutrophil to lymphocyte ratio (NLR) in patients (pts) with recurrent primary malignant brain tumours (PMBT) in Phase I (Ph1) trials: the Royal Marsden (RMH) Experience.
347P. Prognostic value of pre-operative neutrophil-to-lymphocyte ratio in patients with glioblastoma multiforme
348P. The prognostic role of gender and MGMT methylation status in glioblastoma patients: the female power
349P. Reduced-Intensity Bevacizumab in Progressive Glioblastoma Multiforme (GBM) is Associated with Similar Overall Survival versus Standard-Dosing.
350P. An individualized-approach to second-line systemic anti-cancer therapy for glioblastoma
351P. Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated Glioblastoma
352P. The Prognostic Role of Indicators of Systemic Inflammatory Response in Patients with Glioblastoma
353P. Which patients with recurrent Glioblastoma will require a second surgery during their treatment? A machine learning solution
354P. The Prognostic role Of Age In Salvage Re-irridiation Applied Patients With Recurrent Glioblastoma: A Meta-analysis
356P. Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): a mono-institutional prospective study
357P. Dose distribution after tumor cavity injection in brain glioma patients
358P. Retrospective analysis to ascertain whether thromboembolic events, patient gender and tumour size have prognostic implications for glioblastoma multiforme
360P. Primary Central Nervous System Germ Cell Tumours: A Single Institution Retrospective Study
361P. Effect of silibinin nutraceutical supplementation in brain metastases of patients with advanced lung cancer
362P. Melanoma with V600 BRAF mutations and brain metastases. Experience of targeted therapy in a single center.
363P. Radioprotective effect of xenon in radiation treatment for brain metastases
379P. A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study
380P. A phase 1b study evaluating the safety and pharmacokinetics (PK) of regorafenib (REG) in combination with cetuximab (CTX) in patients with advanced solid tumors
381P. Clinical study of Apatinib in the treatment of malignant pleural effusion and malignant celiac effusion
382P. Evaluation of NRP-1 TM domain targeting peptide in Melanoma
383P. A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours
390P. A phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women's cancers
391P. Phase I Expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer
392P. Generation of a novel preclinical PK/PD model provides insights into PARP inhibitor clinical monotherapy activity
393P. Pharmacodynamic (PD) biomarkers for the p70S6K/Akt inhibitor, M2698: translation from animal to human and relevance to dose selection
394P. Phase 1 study of ipatasertib (AKT inhibitor) for investigating safety, tolerability, pharmacokinetics (PK), efficacy, and biomarkers in Japanese patients (pts) with solid tumors including castration-resistant prostate cancer (CRPC)
395P. DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR-TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model
397P. Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination
400P. LCZ 696, administered during doxorubicin, trastuzumab or pertuzumab treatment, prevents cardiotoxicity in our in vitro model
401P. MEK inhibitor retinopathy
402P. A Phase I/II study everolimus in combination with paclitaxel-carboplatin in patients with advanced adenocarcinoma of the stomach
403P. Phase I Studies of the Novel Carcinoembryonic Antigen T-cell Bispecific (CEA-CD3 TCB) Antibody as a Single Agent and in Combination with Atezolizumab: Preliminary Efficacy and Safety in Patients (pts) with Metastatic Colorectal Cancer (mCRC)
404P. Dose escalation study of vemurafenib with crizotinib or sorafenib in patient with BRAF-mutated advance cancers
405P. Hepatic functional imaging and genomics to predict irinotecan pharmacokinetics and pharmacodynamics: The PREDICT IR study:
406P. Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results
408P. Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients
409P. Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies
411P. Pharmacological Activity of CB-103 - An oral pan-NOTCH inhibitor with a novel Mode of Action
413P. RX-3117, a novel Hypomethylating agent, shows promising therapeutic activity in combination with nab-paclitaxel and check-point inhibitors in preclinical models
414P. A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
415P. Population Pharmacokinetic Analysis of OT-101 (Trabedersen) in Patients with Advanced Tumors
416P. An open-label, multicenter phase 1b study of radium-223 + paclitaxel in cancer patients with bone metastases
447P. High hepatic tumor burden and cardiovascular comorbidities linked to carcinoid heart disease
448P. Bone metastases in patients with neuroendocrine neoplasms: a survey of natural history and clinical management
449P. Financial toxicity in patients with neuroendocrine tumors - impact of a chronic disease on patients' economic situation
450P. Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): incidence and impact on quality of life
451P. Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/Depot 120mg in the CLARINET open-label extension
452P. Temozolomide-Capecitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): time to maximum response and optimal treatment duration.
453P. Efficacy of recombinant human endostatin combined with chemotherapy in advanced pancreatic neuroendocrine tumors
454P. Comparison of clinical efficacy of SST analogues therapy (lanreotide Autogel vs. octreotide LAR) in treatment of patients with advance, non-resectable pancreatic neuroendocrine tumours(pNETs).
455P. Metastatic Neuroendocrine Neoplasia (mNEN) Treatments in over 70 Years (y) Old Patients: A Retrospective Outcome Analysis
459P. Follow-up and recurrence in resected gastroenteropancreatic neuroendocrine tumours: A population-based study
461P. The prognostic value of cytokeratin 7, 19, thyroid transcription factor-1 and CD117 expression in lung neuroendocrine tumors of various grades.
465P. Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC): A European subgroup analysis
466P. Mixed Adeno-Neuroendocrine Carcinoma (MANEC) of the gastroenteropancreatic (GEP) tract: a multicentre retrospective study
467P. Incidence of Adrenal gland tumor as a second primary malignancy: SEER based database
468P. Activity of temozolomide (TMZ) in patients (PTS) with malignant pheochromocytoma or paraganglioma (MPP): a mono-institutional retrospective study
469P. Neuroendocrine carcinoma of the uterine cervix: a retrospective monocentric study
487P. Stage-specific treatment of and survival from colorectal cancer: England, Norway and Sweden, 2010-2012
489P. Role of body composition in early stage colorectal cancer (CRC) outcomes
490P. North Japan multicenter phase II study of FOLFOX as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003) - Analysis of Tumor Location.
491P. Factors predicting adherence to a tailored-dose adjuvant treatment based on geriatric assessment in elderly people with colorectal cancer: a prospective study.
492P. Benefits of Upfront Primary Tumour Resection (UPTR) according to sidedness in mCRC: Retrospective analyses of TTD MACRO-2 and PLANET randomised Trials
494P. Short-term clinical outcome from a randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colon cancer: Japan Clinical Oncology Group study JCOG1006
495P. Prognostic Impact of Tumor Deposits in colorectal cancer with lymph nodes metastasis.
496P. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
497P. Tumor-stroma interactions and response to targeted agents in preclinical models of colorectal cancer (CRC)
498P. Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio
499P. The Characteristics and Prognostic Factors in Colorectal Cancer Containing Signet Ring Cell
500P. Effect of lateral lymph node dissection for lower rectal cancer: An ad hoc analysis of the ACTS-RC randomized clinical trial
502P. Effects of mesorectal fascia (MRF) status for locally advanced rectal cancer: Results of a multicenter, randomized, controlled, phase II trial (FDRT-002?
503P. Planned organ preservation for selected T2, T3 rectal cancer. French experience using chemo radiotherapy and Contact X Ray boost
505P. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): final results of the FFCD 1102 phase II trial.
506P. Neoadjuvant treatment with mFOLFOXIRI alone versus chemoradiotherapy in locally advanced rectal cancer: A Propensity Score Analysis from two prospective trials
507P. Updated survival results of FACT trial: Multicenter phase II trial of neoadjuvant chemotherapy with mFOLFOX6 for stage II/III rectal cancer with a T3/T4 tumor.
508P. Phase II randomized trial of capecitabine + radiation therapy with/ without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival.
509P. Immunological features of resected tumor after neoadjuvant chemotherapy (NAC) and chemoradiotherapy (CRT) become the superior prediction markers for recurrence in rectal cancer.
510P. The ADC value of post-RT might predict TRG after neoadjuvant radiotherapy for local advanced rectal cancer
511P. Polyethylene Glycol embolics loaded with irinotecan for chemoembolization of refractory liver metastases from colorectal cancer
512P. Neoadjuvant Systemic Chemotherapy prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the treatment of Peritoneal Carcinomatosis from Colorectal Cancer
513P. Efficacy and tolerability of chronomodulated FOLFIRINOX (chronoIFLO) as 1st or 2nd line treatment in patients (pts) with metastatic colorectal cancer (MCC): final results from an international trial (EORTC 05011)
515P. First-in-Human Phase I Study of Bacterial RNA Interference Therapeutic CEQ508 in Patients with Familial Adenomatous Polyposis (FAP)
516P. A Multicentre Phase I/II Study of TAS-102 with Nintedanib in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (N-TASK FORCE: EPOC1410)
517P. BEACON CRC: Safety Lead-In (SLI) for the Combination of Binimetinib (BINI), Encorafenib (ENCO), and Cetuximab (CTX) in Patients (Pts) with BRAF-V600E Metastatic Colorectal Cancer (mCRC)
518P. Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: a retrospective, registry-based analysis
519P. Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC)
520P. AMALTHEA: A prospective, single-arm study of the Hellenic Cooperative Oncology Group evaluating the efficacy and safety of 1st line FOLFIRI+Aflibercept in patients with metastatic colorectal cancer.
521P. Multicenter phase II study of biweekly XELIRI plus Bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)
522P. Sex-related differences in circadian-dependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O): final results from international randomised time-finding study in patients with metastatic colorectal cancer (MCC).
523P. Mechanism of Pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC)
524P. Bevacizumab first line and impact on subsequent anti-EGFR activity.
525P. Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type Metastatic Colorectal Cancer: A Systematic Review and Metanalysis.
526P. Efficacy of panitumumab and cetuximab in elderly patients (aged ≥ 75) with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC): retrospective analysis of data from nationwide drug-reimbursement-access program
527P. Toxicity and efficacy of flat-dosed versus body-surface area (BSA)-dosed capecitabine
528P. Efficacy of panitumumab and cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC): retrospective analysis of data from nationwide Drug-Reimbursement-Access Program
529P. Multicenter randomized phase II trial (BEVATOMOX) assessing the Raltitrexed, Oxaliplatin and Bevacizumab combination versus FOLFOX6 Bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)
530P. Safety analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
531P. Prognostic factors and specific populations in the pharmacogenetic randomized phase II trial of FOLFIRI with high-dose (HD) of irinotecan vs standard doses in metastatic colorectal cancer (mCRC) patients (pts) according to UGT1A1 genotype.
532P. Analysis of efficacy and prognostic factors in second-line chemotherapy for BRAF V600E mutant metastatic colorectal cancer
533P. A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability
534P. Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial
536P. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study)
537P. P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer
538P. Relationship between pretreatment levels of circulating DNA, circulating tumor cells, CEA, CA19.9 and tumor burden on CT scan in patients treated for a metastatic colorectal cancer
539P. Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISNÚ Program
540P. Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the CAPRI GOIM clinical trial
542P. Circulating tumor (ct) DNA captures intrapatient heterogeneity in metastatic colorectal (mCRC) patients (pts) progressing to FOLFIRI+panitumumab
543P. Dynamic changes in levels of gene mutations using circulating tumor DNA (ctDNA) and efficacy of 1st-line modified (m)-FOLFOXIRI plus bevacizumab (bev) for metastatic colorectal cancer (mCRC) harboring RAS mutation (mt) (JACCRO CC-11)
544P. The frequency of RAS mutation in circulating tumor DNA predicts worse survival in patients with mCRC
545P. Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC)
546P. Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
547P. ULTRA clinical trial: Prospective comparative clinical outcome analysis of three different RAS/BRAF sensitivity mutational cut-offs. A phase II study of the Spanish TTD Group
548P. Prognostic impact of BRAF and KRAS mutations according to the consensus molecular subtypes of colorectal cancer
551P. Comparative and multimodal analysis of the EGFR, HER2, c-MYC, and MET copy number alteration using in situ hybridization in Korean colorectal cancer patients with integration of array-based copy number data from The Cancer Genome Atlas
552P. Mutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer (aCRC) patients (pts): the ROAD study.
553P. First-line panitumumab (P) plus capecitabine (C) for the treatment of elderly patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC). Preliminary results of the phase II, PANEL GITuD-2011-01 study
554P. Prevalence of KRAS/NRAS/BRAF mutations detected by massive parallel sequencing and differential outcomes in MCRC patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy.
555P. Analysis of Angiogenesis Biomarkers for Ramucirumab (RAM) Efficacy in Patients with Metastatic Colorectal Cancer (mCRC) from RAISE, a Global, Randomized, Double-Blind, Phase 3 Study
557P. Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI). Analysis from PRODIGE 9 trial
558P. High PD-L1 expression and high CD8+ T-cell infiltration identifies a new subpopulation of colorectal cancer with high risk of relapse and poor outcome
559P. Clinical impact of molecular positive lymph node status in colorectal cancer
560P. Impact of Immune response-associated gene Polymorphisms on tumor response in Rectal Cancer Patients Treated with capecitabine +/- oxaliplatine and Radiation in the ACCORD-12/PRODIGE-2 phase III trial
562P. Development and validation of multiplex biomarker assay to stratify colorectal cancer (CRC) patient samples into subtypes
563P. HER2 overexpression and amplification in patients with colorectal cancer (HOLIC): A large-scale retrospective study in Chinese population
565P. Whole-exome sequencing of matched germline and plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and identifies mutated KDR/VEGFR2 as new cause of therapy resistance.
566P. The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Colorectal Cancer
567P. Clinical Utility of Quasi-Monomorphic Variation Range (QMVR) on the Determination of Microsatellite Instability (MSI) Status in Patients (pts) with Colorectal Cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01
568P. The impact of antithrombotics on immunochemical fecal occult blood testing for colorectal cancer screening
571P. Multiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles
572P. A robust gene signature for the detection of early relapse in stage I-III colon cancer.
573P. microRNA(miR) subtypes correlates with colorectal cancer(CRC) molecular subtypes . Validation of miR-30b interaction with genes up-regulated in the high-stroma subtype
574P. Gene expression changes in the immunotherapy targets CTLA4 and LAG3 in right- and left-sided colorectal cancer tissues during preoperative oral uracil and tegafur/leucovorin chemotherapy
575P. Prognostic value of microsatellite instability status in stage II/III rectal cancer patients who received upfront surgery
576P. Biomarker testing practices in the SECURE (proSpective obsErvational clinical practiCe stUdy in the first-line management of metastatic colorectal cancer [mCRC] with eRbitux in combination with chemothErapy) study
577P. Exosomal ECM1 protein expression in plasma from the tumor-draining vein (mesenteric vein) and time to relapse in colon cancer patients
579P. Primary Efficacy Results and Clinical Impact of UGT1A1 genotype on Safety from a Phase II Study of FOLFOXIRI plus bevacizumab in Patients with Metastatic Colorectal Cancer: The QUATTRO Study
582P. Cross-Platform comparison for the detection of RAS mutations in cfDNA (NGS strategy, BEAMing assay and ddPCR BioRAD assay)
583P. Impact of Tumor Location on the Efficacy of First-Line anti-EGFR monoclonal antibody plus Chemotherapy in Patients (pts) with Metastatic Colorectal Cancer (mCRC). Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group
584P. Predictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)
585P. Differences in survival (sv) and clinicopathologic characteristics (cpc) between right and left-sided colorectal cancer (CRC), a CARESS-CCR Group Study.
587P. Survival by sidedness of metastatic colorectal cancer (mCRC) treated with Epidermal Growth Factor Receptor Antibodies (EGFR-Ab) in the refractory setting: a population-based study of 1509 patients
588P. Differences in Prescribing Attitudes and Treatment Patterns between Right-sided and Left-sided mCRC in EU5 and the US
589P. Tumor sidedness and enriched gene groups for efficacy of 1st-line cetuximab (cet) treatment in metastatic colorectal cancer (mCRC)
590P. Correlation between RECIST-criteria, Morphologic Response by CT and Pathologic Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET study
591P. Tumor staging with magnetic resonance imaging after neoadjuvant chemoradiation for Locally Advanced Rectal Cancer and comparison of pathologic staging
592P. Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): results from the FOXFIRE prospective randomized studies
593P. Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial
594P. Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer
596P. Chemotherapy-induced thrombocytopenia (CIT) in metastatic colorectal cancer (mCRC) patients
597P. Real world use of palliative systemic therapy (tx) in patients (pts) with metastatic early onset colorectal cancer (mEOCRC) within a UK specialist cancer centre
599P. Real life registry data of primary localisation of a well-defined colon cancer population of Western Austria (Salzburg, Tyrol and Vorarlberg), Eastern Switzerland (St.Gallen and Graubünden) and Liechtenstein.
600P. Improving visualization and adherence by converting the Dutch colorectal cancer guidelines into decision trees: the Oncoguide project
601P. Colon and rectal cancer incidence are rising among young Europeans: Results from the cancer registry of Crete.
602P. Epidemiology of colorectal cancer in Korea: Korean National Health insurance bigdata analysis
603P. Watch and Wait versus Surgery with Pathological complete response: single institution experience
604P. A Retrospective Cohort Study Evaluating the Safety and Efficacy of TAS-102 in Patients with Metastatic Colorectal Cancer [HGCSG1503]: Updated analysis
606P. Clinical manifestations and prognostic factors of bone metastasis in colorectal cancer
608P. Variations in clinicopathological features, treatment patterns, and outcomes of young adults with colorectal cancer in the United States and Egypt
628P. Treatment Outcome of gastric cancer associated with esophageal cancer
631P. Prognostic stratification of pathologic stage in patients with preoperative chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
632P. Thromboembolic complications in patients with oesophagogastric adenocarcinoma undergoing preoperative chemotherapy
634P. Risk of second malignancies after definitive therapy for esophageal cancer: a competing risk analysis
636P. Recent advance in enhanced recovery after esophagectomy: a systematic review and meta-analysis
637P. High thromboembolic event rate in patients with locally advanced esophageal cancer during perioperative therapy. A pre-planned analysis of the intergroup phase III trial SAKK 75/08.
638P. Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07)
640P. Dual CDK 4/6 inhibitor demonstrates potent antitumor efficacy in vitro and in vivo against esophageal adenocarcinoma
641P. The influence of body composition on the systemic exposure of paclitaxel in esophageal cancer patients
642P. Survival in advanced oesophagogastric adenocarcinoma (OGA) improves with the use of multiple lines of therapy: results from an analysis of over 500 patients (pts)
643P. The Research Progress in Randomized, Multicenter, Controlled Evaluation of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients
647P. ATM loss, MSI and survival in the MAGIC trial
648P. Negative Lymph Node Count is a Significant Prognostic Factor in Patient with Stage IV Gastric Cancer after Palliative Gastrectomy
651P. Is there any relationship between Helicobacter pylori infection and HER2 expression in gastric cancer?
652P. Iron Deficiency Anemia in Gastric Cancer: A Canadian Single Site Retrospective Cohort Study
653P. Is surgical resection beneficial in recurrent or metastatic gastric cancer?
655P. Safety of neoadjuvant/adjuvant chemotherapy for gastroesophageal cancers: A single cancer centre experience
656P. Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy in Gastric Cancer Patients with Peritoneal Metastasis
657P. Nutritional recovery after open and laparoscopic distal gastrectomy for early gastric cancer: A prospective multicenter comparative trial (CCOG1204)
659P. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in advanced gastric cancer: AGAMENON study data
661P. Bidirectional chemotherapy in gastric cancer (GC) with peritoneal carcinomatosis (PC) combining intravenous chemotherapy with pressurized intraperitoneal aerosol chemotherapy (PIPAC): results of 103 procedures in 52 patients
662P. Gastrectomy after response to intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology
663P. Change in the molecular profile of tumor tissues during treatment with trastuzumab, as analyzed by next-generation sequencing and immunohistochemistry—A multicenter prospective biomarker study on HER2-positive gastric cancer
665P. Modified Glasgow prognostic score, prognostic nutritional index and ECOG score could be new prognostic factors for survival in metastatic gastric cancer.
666P. Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised phase 2 trial of regorafenib in advanced gastric cancer
668P. Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: the "Gastric Life" nomogram
669P. TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas.
670P. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
671P. Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
672P. A multicentre, Phase II Study with Cabazitaxel in Previously Treated Patients with Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach (CABAGAST)
673P. Comparison of cytotoxic backbones for first line trastuzumab-containing regimens in HER2-positive advanced esophagogastric cancer: A meta-analysis.
674P. Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: CheckMate 032
675P. Involvement of the immunoregulator MZB1 in progression of gastric cancer
676P. PD-L1 immunohistochemistry (IHC) by three different assays and molecular profiling in tissue microarray (TMA) of gastric cancer
677P. Treatment of advanced gastric cancer based on Lauren's histological: Real-World Data from the AGAMEMON National Cancer Registry
679P. Safety and efficacy of S-1 treatment in elderly patients with advanced or recurrent gastric cancer: a subgroup analysis from the phase III JFMC36-0701 trial
681P. Clinical impact of programmed death ligand-1 and -2 expression after platinum based chemotherapy in metastatic gastric cancer
682P. Clinical practice observation of trastuzumab (TRA) in patients (pts) with HER2-positive metastatic adenocarcinoma of the stomach (mGC) or the gastro-oesophageal junction (GEJ) - final analysis from the German non-interventional study HerMES
684P. Targeting c-Met and DNA Double-Strand Break (DSB) Repair Pathways for BRCA-mutated gastric carcinomas
685P. Clinical efficacy observation for Endostar combined with chemotherapy treating gastric cancer peritoneal carcinomatosis
687P. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.
688P. Beyond first line treatment for advanced esophagogastric adenocarcinoma (EGAC): a phase 1 dose escalation study of Regorafenib (Reg) combined with Paclitaxel (PTX) (REPEAT study)
689P. Phase I dose escalation study with expansion cohort of the addition of Nab-Paclitaxel (nab-P) to capecitabine and oxaliplatin (CAPOX) as first line treatment of advanced esophagogastric adenocarcinoma (EGAC) (ACTION study).
691P. Inter-patient and intra-tumoral heterogeneity of oncogenic copy number alterations (CNAs) in gastric and gastroesophageal junction (GEJ) adenocarcinomas
692P. Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening.
693P. Prognostic effect of surgery of metastases in patients with advanced gastric cancer: real-world data from the AGAMENON registry
696P. Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: an exploratory analysis of a phase II trial, CCOG1303
697P. Detection of microsatellite instability (MSI) with a novel panel of biomarkers in gastric cancer samples
698P. A Dose-Response Study of Ramucirumab Treatment in Patients with Gastric Cancer/Gastroesophageal Junction Adenocarcinoma: Primary Results of 4 Dosing Regimens in the Phase 2 Trial I4T-MC-JVDB
700P. Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian Multi-center HCC Database
701P. Final data from a phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC)
702P. Correlation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC)
705P. Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial
706P. Overall survival (OS) by platelet count at baseline in patients with hepatocellular carcinoma (HCC) treated with sorafenib (SOR) in the SHARP and AP trials and regorafenib (REG) in the RESORCE trial
707P. Network Meta-Analysis (NMA) of Treatments for Unresectable Hepatocellular Carcinoma (uHCC)
ePoster708P. Epidemiological study of histologically proven advanced hepatocholangiocarcinoma : an AGEO multicenter retrospective study
709P. A phase II study of sorafenib and yttrium-90 glass microspheres for advanced hepatocellular carcinoma, BCLC stage C.
710P. Understanding the distribution and clinical impact of HFE polymorphisms on the cancer risk of over 50, 000 volunteers in a single U.S. health care system.
711P. Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study)
712P. Effect of adjuvant chemotherapy and chemoradiotherapy in patients with ampullary carcinoma: A NCDB analysis
713P. The mutational landscape of periampullary adenocarcinomas in relation to morphological subtype and patient survival
ePoster714P. Gemcitabine and platinum- based chemotherapy in first line treatment of hepatocholangiocarcinoma : an AGEO multicenter retrospective study
716P. The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced biliary tract cancer.
717P. Prognostic implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma (iCCA) Treated with First-line Gemcitabine Plus Cisplatin (GEMCIS)
718P. Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC)
720P. Inoperable Carcinoma Gallbladder: Comparison of two palliative Chemotherapy regimens (Gemcitabine-Platinum versus CAPEOX)
721P. Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cut-off Value
722P. A Phase 2 Study of Lenvatinib Monotherapy as Second-line Treatment in Unresectable Biliary Tract Cancer: Primary Analysis Results
723P. Genotyping and mRNA profiling reveal actionable targets in biliary tract cancers.
724P. HER-2/HER-3 pathway as a potentially-actionable target in biliary tract cancers (BTCs): a retrospective analysis
725P. Actionable molecular alterations in advanced biliary tract carcinomas: preliminary data from the ProfiLER program (NCT01774409)
726P. Precision medicine for patients with advanced biliary tract cancers: updated results from the prospective MOSCATO trial
727P. Preoperative chemoradiotherapy after induction FOLFIRINOX improve R0 resection margins rate and histological response in patients secondary resected in borderline or locally advanced pancreatic adenocarcinoma.
728P. Intratumoral heterogeneity of SMAD4 immunohistochemical (IHC) expression and its role in prediction of recurrence patterns in patients with resectable pancreatic cancer (PC)
729P. Outcome of patients with pancreatic adenocarcinoma with complete pathological response following neo-adjuvant therapy
730P. Interim Health Related Quality of Life (QoL) from LAPACT, a Phase 2 Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (G) for Patients (Pts) With Locally Advanced Pancreatic Cancer (LAPC)
732P. Should pancreatic cancer be included in BRCA1/2 testing criteria?
733P. Sequential Chemo-chemoradiation (CCRT) in Locally Advanced Pancreas Cancer in an Irish High Volume Centre
736P. Randomized phase 2 trial of peri- or post-operative chemotherapy in resectable pancreatic adenocarcinoma
737P. TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: results from the CONKO-001 study
738P. Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC)
739P. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
740P. The impact of UGT1A1 genetic polymorphism on safety in unresectable pancreatic cancer patients receiving FOLFIRINOX therapy: A subset analysis of JASPAC 06 study
741P. Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone
743P. Tumor Hyaluronan (HA) is a Novel Biomarker: Results of the Randomized Phase 2 HALO 202 Study of PEGPH20 Plus nab-Paclitaxel/Gemcitabine (PAG) vs AG in Previously Untreated, Metastatic Pancreatic Ductal Adenocarcinoma (mPDA)
744P. Overall Survival and Immunologic Responses in Metastatic Pancreatic Adenocarcinoma (PDAC) on PEGylated Human IL-10 (AM0010) with 5-FU/LV and Oxaliplatin (FOLFOX)
745P. Circulating levels of ADAM12, a stromal activation biomarker, are predictive of survival in pancreatic ductal adenocarcinoma (PDAC)
746P. COnsensus statement on Mandatory Measurements in PAncreatic Cancer Trials for systemic treatment of unresectable disease (COMM-PACT)
747P. phase I study of resminostat/S-1 combination in patients with pre-treated biliary tract or pancreatic cancer
748P. Comparisons of Outcomes of Patients with Advanced Pancreatic Cancer (APC) Treated with FOLFIRINOX (FX) Versus Gemcitabine and Nab-Paclitaxel (GN): A Population-Based Cohort Study.
749P. Musculoskeletal Events (MSEs) with PEGPH20 Treatment and Management in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDA)
750P. Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma
752P. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: a subset analysis from the nation-wide multicenter observational study (JASPAC06)
753P. Quality of Life (QoL) of patients (pts) with metastatic pancreatic cancer (mPAC) initiating first-line chemotherapy (CT) in routine practice
754P. Impact of the duration of diabetes mellitus (DM) on the outcomes of metastatic pancreatic cancer (mPC) treated with gemcitabine (G): a retrospective study
755P. Prognostic Value of Neutrophil-Lymphocyte Ratio in First Line Treatment for Metastatic Pancreatic Adenocarcinoma
756P. Treatment patterns, clinical characteristics, and outcomes of patients (pts) with metastatic pancreatic cancer (MPC) treated with nab-paclitaxel (nab-P) plus gemcitabine (GEM) in real-life practice. ANICE-Pac trial.
757P. Safety and efficacy of Gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis.
758P. Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer
759P. PANOVA: A phase 1/2 study of TTFields (150 kHz) with concomitant standard chemotherapy for front-line advanced pancreatic adenocarcinoma - Updated efficacy results
761P. A Phase I study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastasized pancreatic cancer
ePoster762P. Impact of advances in systemic chemotherapy for unresectable Pancreatic Ductal Adenocarcinoma (PDAC) in Alberta, Canada
764P. Crucial relationship of Neural Wiskott Aldrich syndrome protein(N-WASP) and Lysyl oxidase-like 2(LOXL2) in the promotion of pancreatic cancer metastasis
765P. The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Small Intestine Cancer.
766P. Frequent ERBB3 (HER3) activating mutations in small bowel adenocarcinomas
794P. EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy
796P. Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases
797P. Phase II Trial of SM88 in Non-Metastatic Biochemical Recurrent Prostate Cancer
798P. Impact of the addition of metformin (Met) to abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing on Abi treatment: a phase II pilot study
799P. Steroid switch: Reversal of resistance to abirateron acetate (AA) and prednisolone (P) combination in metastatic castration-resistant prostate cancer (mCRPC) patients
800P. Phase II study of Prednisone-Dexamethasone switch in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Abiraterone and Prednisone (AA+P)
802P. Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): results from the CABADOC randomized trial
803P. Indirect Comparison of Abiraterone Acetate Plus Prednisone and Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer
804P. Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Evidence From the Veterans Health Administration
805P. Efficacy and safety of first-line combined androgen blockade in advanced prostate cancer: A meta-analysis
806P. Outcomes of Prechemotherapy (pCRx) Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Multi-Institution Hospital-based Registry.
807P. First Interim Results of the Radium-223 (Ra-223) REASSURE Observational Study: Analysis of Patient (Pt) Characteristics and Safety by Use of Abiraterone and/or Enzalutamide (Abi/Enza)
808P. A Phase II Study of Enzalutamide (Enz) with Dutasteride (Dut) or Finasteride (Fin) in Men ? 65 Years with Hormone-naive Systemic Prostate Cancer (HNSPCa)
809P. Cabazitaxel plus prednisone and prophylaxis of neutropenia complications in the treatment of metastatic castration-resistant prostate cancer after failure to docetaxel: a multicenter, non-comparative, open-label, phase IV study
810P. Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25 mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
811P. Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A Randomized, Open Label, Phase III, Multicenter trial.
815P. Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with Abiraterone in pre-docetaxel setting
816P. 68Ga-PSMA-PET/CT as a practice changing tool in biochemically recurrent prostate cancer
818P. PSA Doubling Time (PSADT) and Proximal PSA Predict Metastasis-Free Survival (MFS) in Men with Biochemically Recurrent Prostate Cancer (BRPC) after Radical Prostatectomy (RP): Implications for Patient Counseling and Clinical Trial Design
820P. Combining functional imaging with circulating biomarker analysis to improve prognostication of metastatic castration-resistant prostate cancer (mCRPC)
821P. A Polymorphism in the Promoter of the FRAS1 Gene is Associated with Metastatic Prostate Cancer
823P. Expression of Steroid Hormone Transporter, SLCO1B3, is Mediated by a CBP/p300 Regulatory Mechanism in Prostate Cancer
824P. ARV7 status and CTC count. A combined biomarker for the baseline therapeutic decision in each line of mCRPC treatment
826P. Prevalence and baseline clinico-pathological associations of germline deleterious mutations in DNA repair genes (gmDDR) in a metastatic castration resistant prostate cancer (mCRPC) prospective spanish cohort (PROREPAIR-B study).
827P. Comprehensive characterization of BRCA1 and BRCA2 alterations in circulating tumor DNA and tumor tissue in men with prostate cancer: implications for clinical care
828P. Durable Prostate Cancer Control in a Randomized Trial of Optimal Timing of Dose Escalated (76 Gy) Radiation and 6 months ADT in Prostate Cancer
829P. Initial Results From AQUARiUS, a Prospective, Observational, Multi-Centre Phase 4 Study Assessing Patient-Reported Outcomes (PROs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts) Treated With Abiraterone Acetate Plus Prednisone (AAP) or Enzalutamide (ENZ)
830P. Assessment of association between clinical characteristics and prostate specific antigen (PSA) progression in men with prostate cancer (PCa) receiving a leuprorelin acetate implant: results from the non-interventional German cohort LEAN study
831P. Neuropsychiatric adverse events of enzalutamide and abiraterone acetate plus prednisone treatment: Contrasting a meta-analysis of randomized clinical trials with real world reporting patterns from EUDRA
832P. Influence of an international consensus conference on practice patterns in advanced prostate cancer (APC)
833P. Postoperative Radiation Therapy After Radical Prostatectomy
84PD. Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028)
856P. Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN Solid Tumor study: updated analysis with ≥12 months of follow-up in all patients
857P. Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status
858P. Trial of Sacituzumab Govitecan (IMMU-132) in Patients with Pretreated Metastatic Urothelial Cancer (PRUC): Interim Results
859P. Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels
85PD. Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT).
860P. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination (GE) In Cisplatin Ineligible Patients (pts) with Metastatic Urothelial Carcinoma (mUC): Efficacy Report (NCI-9653; 1UM1CA186717, NO1-CM-2011-00038)
861P. Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma
862P. Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
863P. Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)
864P. Long non-coding RNAs are differentially expressed between bladder cancer subtypes.
865P. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration
866P. Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC).
867P. Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC)
868P. Comparison of circulating tumor DNA (ctDNA) profile in metastatic urothelial carcinoma (mUC) derived from the upper tract (UT) and lower tract (LT)
869P. Modeling of Tumor Kinetics and Overall Survival to Identify Predictive Factors for Efficacy of Durvalumab in Patients with Urothelial Carcinoma (UC)
86PD. Biomarker prevalence study and Phase I trial of afatinib in children with malignant tumours
870P. Expression of Galectin-1 Determines Tumor Recurrence and Cancer-specific Survival in Patients with pT3 Upper Urinary Tract Urothelial Carcinoma
871P. Identification of genomic features underlying response of muscle-invasive bladder cancer (MIBC) to neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) in an open-label, single-arm, phase 2 study
872P. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC)
873P. RX-3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Advanced Urothelial Cancer
874P. Immune Correlates for the Efficacy of PEGylated Human IL-10 (AM0010) with Nivolumab in Renal Cell Cancer
875P. Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: focus on a special patient population
876P. Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic Renal Cell Carcinoma (mRCC): the Gustave Roussy experience.
877P. Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice
878P. Comparing ITC Results From Lenvatinib Plus Everolimus for Second-line Treatment of Advanced/Metastatic Renal Cell Carcinoma: Crossover Versus No Crossover
87PD. Prospective study assessing the expression of angiogenesis-related genes as markers of anti-VEGFR2 response in advanced renal cell carcinoma
881P. Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial
882P. Potential impact of avelumab+axitinib (A+Ax) on tumor size (TS) compared with historical data of sunitinib (S) as evaluated by a modeling and simulation (MS) approach
883P. Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy
884P. SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): ineligible (I) vs eligible (E) patients for clinical trials.
885P. Sunitinib Versus Pazopanib for Patients with Metastatic Renal Cell Carcinoma: Two Turkish Hospital Experience, A Retrospective Comparative Case Series Study
886P. SPAZO2 (SOGUG): Comparative effectiveness of everolimus (Ev) vs axitinib (Ax) as second-line after first-line pazopanib (1stPz) in metastatic renal carcinoma (mRC).
888P. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC)
889P. Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients
890P. Prospective comparison of RECIST and alternative response assessment criteria in the evaluation of metastatic renal cell cancer patients from phase II of the multi-centre randomised STAR trial
891P. Outcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy
892P. Treatment beyond progression in patients with advanced RCC participating in the Expanded Access Programme (EAP)
893P. Improved long-term clinical outcomes and safety profile of sunitinib dosing schedule with 4/2 switched to 2/1 in patients with metastatic renal cell carcinoma
894P. A retrospective study of the management of metastatic renal cell carcinoma brain tumors
895P. SPAZO2 (SOGUG): Validation of the International Metastatic Database Consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC).
900P. Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data.
901P. Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)
902P. Prognostic factors for overall survival of patients with advanced renal cell carcinoma - data from the German prospective RCC-Registry
903P. The efficacy and safety of sorafenib in patients with renal insufficiency of advanced renal cell carcinoma: real- world data of sorafenib in Japan.
905P. CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
906P. Impact of haptoglobin polymorphism on survival of renal cell carcinoma patients
908P. Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
909P. Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma - data from the German prospective RCC-Registry group
910P. Exome Sequencing of Tumor Samples from S1107 "Randomized Phase II Evaluation of Tivantinib and Tivantinib in Combination with Erlotinib in Patients with Papillary Renal Cell Carcinoma (pRCC)"
911P. Patients (pts) with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with Nivolumab (Nivo) based immunotherapy as advanced treatment (ATL) line: analysis of a national early access program (EAP)
912P. Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): a retrospective study
913P. Avelumab in patients with metastatic adrenocortical carcinoma (mACC): results from the JAVELIN Solid Tumor trial
914P. Do patients (pts) with advanced nonseminomatous germ cell tumors (aNSGCT) and unfavorable time to normalization (TTN) of tumor markers benefit with prolongation of 1-st line chemotherapy (ChT)?
915P. The prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors
916P. Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non seminoma (S) using miR371
917P. A Single Centre Retrospective Review of Testosterone Deficiency in Germ Cell Cancer Patients
945P. Evaluation of circulating tumor DNA in patients with ovarian cancer harboring somatic PIK3CA or KRAS mutations
946P. Predictive and prognostic value of tumor cells and circulating plasma free DNA in advanced epithelial ovarian carcinoma
948P. Genomic instability is associated with increased immune infiltration and PDL1 expression in epithelial ovarian cancer
950P. Gene mutational analyses in 154 ovarian cancer (OC) samples from the ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC
951P. A Retrospective Study of Endocrine Therapy in High Grade Serous Ovarian Carcinoma.
952P. Randomised prospective study of maintenance tamoxifen versus post adjuvant chemotherapy surveillance only in advanced ovarian cancer patients
954P. Prospective cohort study of bevacizumab plus standard platinum based chemotherapy?as front-line treatment for advanced epithelial ovarian cancer, fallopian tube cancer, or?primary peritoneal cancer: Japanese Gynecologic Oncology Group study (JGOG3022)
955P. A Landmark Analysis of Overall Survival in PR-OC Patients Treated with Chemotherapy and Bevacizumab using Early Tumor Shrinkage as Covariate
956P. Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC)
957P. Feasibility and effectiveness of multiple lines of bevacizumab-based therapy in patients with recurrent tuboovarian carcinoma
958P. Impact of body mass index on outcome in 785 patients receiving systemic chemotherapy and bevacizumab for primary advanced ovarian cancer
959P. A prospective study to evaluate the role of Cytoreductive surgery (CRS)+ HIPEC in advanced epithelian ovarian malignancy -100 consecutive cases -INDIAN experience
960P. Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer
961P. ICON7: ovarian cancer, platinum second-line chemotherapy and overall survival
962P. Disease Burden During the "Watchful Waiting" Period in Patients with Recurrent Ovarian Cancer
964P. Modeling and Impact of Organ Function on the Population Pharmacokinetics (PK) of Niraparib, a Selective Poly (ADP-Ribose) Polymerase (PARP)-1 and -2 Inhibitor
965P. Evaluation of tumour responses in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) from the Phase III SOLO2 trial of olaparib maintenance monotherapy (ENGOT Ov-21)
966P. Outcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study
968P. PRO-002, a Phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancer
969P. Phase 1/2 trials of peptides cocktail vaccine for resistant cervical and ovarian cancer. Qol analysis
970P. A Phase 1 Study of Selinexor (S) in Combination with Paclitaxel (P) and Carboplatin (C) in Patients (pts) with Advanced Ovarian (OC) or Endometrial Cancers (EC).
971P. Pazopanib and oral Cyclophosphamide in women with Platinum resistant Epithelial Ovarian Cancers
972P. Apatinib as a salvage treatment in gynecologic cancer patients failed from two or more lines of prior chemotherapy
973P. A GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC)
ePoster974P. Reproductive function in patients (pts) with malignant ovarian germ cell tumors (MOGCT) following chemotherapy (ChT)
975P. Preoperative MRI Versus Intra-operative Frozen Section in Surgical Management of Clinically Early Endometrial Cancer
976P. Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients
977P. Is chemotherapy worthwhile in patients with FIGO stage 1B, lymph nodes negative, grade 3 endometrial cancer?
979P. Achievement of complete response (CR) in metastatic or recurrent cervical cancer (MRCC): Does it matter?
980P. Factors Negatively Affecting Voluntary Cervical Cancer Screening Among Educated Indians Above Poverty Line
982P. Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma.
1010P. Event free survival at 24 months. A new endpoint in Diffuse large B cell lymphoma.
1012P. Role of prephase treatment prior to definitive chemotherapy in diffuse large B -cell lymphoma (DLBCL)
1013P. The Role of FDG-PET/CT in Detecting Bone Marrow involvement in Diffuse Large B-Cell Lymphoma
1014P. Evaluation of various prognostic scores and impact of cell of origin on survival in Limited stage DLBCL: Retrospective study.
1016P. Autologous stem cell transplantation (ASCT) is safe and effective for the treatment of Non-Hodgkin Lymphoma (NHL) in an elderly population of patients over 65 years old: a single center experience
1017P. Phenotypic and Functional Characterization of Tumor Infiltrating Lymphocytes (TIL) Grown from Non-Hodgkin Lymphoma Tumors - Implications for the Development of Novel Therapies for Lymphoma
1018P. International prognostic scores (IPS-7, IPS-3 and IPS-3 new) for prediction of FFS and OS in cases with Hodgkin Lymphoma. Which is more practical and accurate?
1019P. Evaluation of indoleamine 2,3-dioxygenase expression (IDO), transforming growth factor beta (TGF-β) and interleukin 13 (IL13) expression on clinical outcome in patients with Hodgkin's lymphoma.
1020P. Clinical impact of atypical phenotypes in Adult T-Cell Lymphoma/Leukemia among HTLV carriers
1021P. Evaluation of the PI3K Pathway in Peripheral T-cell Lymphoma
1022P. Safety and Tolerability of Chemotherapy (CT) Containing High Doses of Methotrexate (HD-MTX) and Cytarabine (Ara-C) in Patients with Primary Central Nervous System Lymphoma (PCNSL) and Hepatitis B Virus (HBV) Infection
1023P. Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
1024P. Clinical impact of FISH analysis in extramedullary plasmacytomas
1025P. Independent predictors of one year mortality in patients with primary systemic immunoglobulin light chain cardiac amyloidosis
1026P. Endoscopic evaluation of acute intestinal GVHD after allogeneic hematopoietic cell transplantation?
1027P. Surveillance stool culture and its association with febrile neutropenia in patients with Acute Leukemia (AL) undergoing induction chemotherapy.
ePoster1028P. L-arginine - targeted for the anthracycline cardiotoxicity prevention in patients with acute leukemia of high cardiological risk
1029P. Multiple myeloma complicated by concomitant cardiac pathology
1030P. Evaluation of dose intensification of cytarabine in postremission therapy in older AML patients within the prospective phase II AMLSG 06-04 study
1031P. The EUROSKI Biomarker Study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia.
1033P. Quantitative Assessment of Inotuzumab Ozogamicin (InO) Response Relative to Investigator's Choice of Chemotherapy (ICC) in Adults With Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (ALL)
1057P. Phase I trial of cetuximab, intensity-modulated radiation therapy, and ipilimumab in previously untreated, locally advanced head and neck cancer
1058P. Does hyper-progression exist among head and neck cancer patients treated with immunotherapy?
1059P. PD-L1 Detection and Assay Performance in Squamous Cell Carcinoma of the Head and Neck Using PD-L1 IHC 28-8 pharmDx
1060P. Programmed death ligand-1overexpression is a poor prognostic factor for Human papillomavirus-positive tonsillar squamous cell carcinoma
1061P. The prognostic role of PD-L1 expression in tumor and immune cells in oral cavity squamous cell carcinoma
1062P. Immune profile analysis of head and neck squamous cell carcinoma before and after neoadjuvant treatment with the IRX-2 regimen
1063P. Phenotyping of the immune infiltrate in oropharyngeal squamous cell carcinoma: focus on materials and methods.
1065P. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck - A multicentre, retrospective analysis
1068P. The observational ENCORE study: cetuximab + platinum-based therapy (PBT) for first-line (1L) treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
1069P. Primary surgery versus chemoradiotherapy for advanced oropharyngeal and hypopharyngeal cancer: a propensity-score matched study using a nationwide database
ePoster1070P. Comparison of carboplatin with 5-fluorouracil (carbo-5FU) versus cisplatin as concomitant chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
1071P. Postoperative radiotherapy with weekly cisplatin in locally advanced head and neck cancer
1072P. Effectiveness and Toxicities of Cetuximab in Combination with Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Score-matched Analysis
1073P. Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: Indian rural Hospital experience
1074P. A phase II study of combination chemotherapy with cetuximab/S-1/low dose cisplatin as neoadjuvant manner for oral squamous cell carcinoma patients.
1075P. Role of induction chemotherapy in locally advanced T4b oral cavity cancers: A single Institute experience
1076P. Concurrent chemoradiotherapy (CCRT) versus induction docetaxel, cisplatin and 5-fluorouracil (TPF) followed by CCRT in locally advanced hypopharyngeal and base of tongue cancer: A randomized phase II study
1077P. Do patients over 70 years with advanced head and neck squamous cell carcinoma tolerate curative intent concurrent chemo-radiation? Predictors of oncological outcomes
1078P. Multidisciplinary Team Management in Head and Neck Cancer: the real life experience.
1079P. Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): analysis of the LUX-Head & Neck 1 (LHN1) trial
1081P. Benefit of Cetuximab addition to a platinum-Fluorouracil-based chemotherapy in an unselected population of metastatic head and neck cancer patients and effect of KRAS Lcs6 variation on Cetuximab response
1082P. A Pilot Study of Apatinib in Heavily Pretreated Metastatic adenocarcinoma of the Head and Neck
1083P. Natural history and prognostic factors of head and neck cancer patients with bone metastases: a retrospective Italian study
1084P. Prognostic impact of the Neutrophil-to-Lymphocyte Ratio (NLR) on overall survival in patients treated with chemoradiotherapy for head and neck cancer
1086P. Diagnostic and Prognostic Impact of Plasma Osteopontin in Nasopharyngeal Carcinoma
1087P. Head and neck cancer (HNC) and synchronic lung cancer: impact of the lung cancer on the management and prognosis of these patients. Data from the SYNCHRON GFPC 15-04 Study
1088P. An Estimation of the Population Survival Benefit of First-course Chemotherapy for Head and Neck Cancers.
1090P. Analysis of the impact of the tumours committee on the multidisciplinary approach to head and neck epidermoid cancer in our institution
1091P. Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC)
1093P. Resource-Stratification of National Comprehensive Cancer Network (NCCN®) Head and Neck Cancers Guideline
1094P. Long-term results of chemoradiotherapy for stage III nasopharyngeal carcinoma patients and risk grouping by pretreatment EBV viral load
1095P. Nasopharyngeal cancer in children: Long term results The experience of the university hospital of Sfax (Tunisia)
1098P. Incidence and impact of DPD mutation on neoadjuvant chemotherapy in head and neck cancers
1100P. The phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for head and neck cancer patients
1101P. Oral mucosa dose parameters predicting grade 3 acute toxicity in locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemotherapy
1102P. Sinonasal non glandular cancers relapsing after multimodal treatments
1103P. Survival outcome and optimal treatment of intermediate-grade salivary gland carcinoma
ePoster1104P. Incidence and survival of secondary malignances (SM) in oropharingeal squamous cell carcinoma (OPSCC): a homogeneous single report institution
1114P. All.Can initiative - improving efficiency in cancer care
1115P. Cost-effectiveness of nivolumab+ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067
1116P. Palbociclib in advanced breast cancer: a cost-utility analysis
1118P. Health related quality of life and utility weights of Medical Oncology inpatients
1119P. A trial-based EUROQOL EQ-5D health utility analysis in patients with classical Hodgkin lymphoma
1121P. Costs of Dacomitinib versus Placebo in Pretreated Unselected Patients (Pts) with Advanced NSCLC: CCTG BR.26
1122P. Feasibility of Routine Collection of Health State Utilities using EQ-5D in a Breast Cancer Outpatient Clinic
1123P. Estimating the drug treatment cost of breast cancer
1124P. Impact of licensing and reimbursement discrepancies on patient access to cancer treatments across Europe and Canada
1125P. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer
1126P. The evolution of value with filgrastim in oncology
1128P. Anti-PD1 inhibitors: assessment of proper use, efficacy and economic impact in daily practice
1129P. Real World Treatment Costs and Resource Utilization among Patients with Metastatic Bladder Cancer
1130P. Investigating discrepancies in assessments of PFS by study investigators and independent review
1131P. Medical Costs and Health Care Resource Use (HCRU) in Elderly US Patients (pts) With Newly Diagnosed Metastatic or Surgically Unresectable Urothelial Carcinoma (mUC) Using Surveillance, Epidemiology, and End Results (SEER) Medicare Data
1132P. Chasing the survival curve tail: The effect on Cost-Effectiveness of Nivolumab for Second-line Treatment of Advanced Renal Cell Carcinoma
1134P. Changing treatment patterns in metastatic colorectal cancer in EU5 countries from 2014 to 2016
1150P. Phase II clinical trial of peptide vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS.
1152P. Phase 1 study of HSP105-derived peptide vaccine for patients with advanced esophageal cancer/ colo- rectal cancer.
1153P. An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer
ePoster1157P. Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors
1158P. Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?
1159P. Long Term Survival in Patients Responding to an Anti-PD-1/PD-L1 Therapy and Disease Outcome Upon Treatment Discontinuation
1160P. Meta-Analysis of Anti-PD-1/PD-L1 Therapy Related Adverse Events in Clinical Trials
1161P. A Standardized Comparison of Outcomes in Patients (Pts) With Refractory, Aggressive Non-Hodgkin Lymphoma (rNHL) from the SCHOLAR-1 Analysis and the ZUMA-1 Study of Axicabtagene Ciloleucel (axi-cel)
1162P. Predictive factors for poor progression-free survival in patients with non-small-cell lung cancer treated with nivolumab
1163P. Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience
1164P. Patterns of progression under antiPD1/PDL1 in advanced NSCLC patients allow discriminating pseudo-progression from real progression.
1165P. Immune checkpoint Inhibitors following targeted therapies in MITF family translocation renal cell carcinomas
1166P. Tumor Flare Reaction (TFR) in Cancer Treatments: A Systematic Review.
1168P. Estimation of benefice to anti-PD-(L)1 for metastatic patients by real-time quantitative and functional estimation of immune infiltrate with RNAseq
1169P. Topography of Tumor Mutational Burden (TMB) and Immune-related Genomic Alterations (GA) Across Gastrointestinal Malignancies (GIm): A Study of 22,570 Cases
1170P. Analysis of POLE mutation and Tumor Mutational Burden (TMB) Across 80,853 Tumors: Implications for Immune Checkpoint Inhibitors (ICPIs)
1171P. Checkpoint inhibitors in MSI tumors: Lessons from a monocentric experience
1172P. Single Nucleotide Polymorphisms in PD-L1 and outcome in Nivolumab-treated Advanced Non-Small-Cell Lung Cancer Patients
1174P. KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p). Experience from a single institution.
1175P. Comparability of programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating immune cells (IC) and tumor cells (TC) in advanced urothelial bladder cancer (UBC) using clinically relevant immunohistochemistry (IHC) assays
1177P. Undiscovered immune heterogeneity in pancreatic adenocarcinoma (PDAC)
1178P. Optimized protocols to determine PD-L1 expression on tumor tissue and cytology samples from non–small cell lung cancer (NSCLC) patients using the 22C3 antibody with various immunohistochemistry (IHC) autostainers
1180P. Development of OAT-1746: a Novel Arginase 1 and 2 Inhibitor for Cancer Immunotherapy
1181P. Pharmacokinetics (PK) and Pharmacodynamics (PD) of cergutuzumab amunaleukin (CA), a carcinoembryonic antigen (CEA)-targeted interleukin 2 variant (IL2v) with abolished binding to CD25
1182P. A First-in-Human Study of a Novel Monoclonal Antibody INCSHR01210 Directed Against Programmed Cell Death Protein 1 (PD-1) in Patients with Advanced or Metastatic Cancer
1183P. Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF 06801591, an anti-PD1 antibody administered intravenously (IV) or subcutaneously (SC)
1184P. A Phase I/II Safety Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Solid Tumors
1185P. Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti–PD–1 monoclonal antibody, in patients (pts) with advanced solid tumors
1187P. A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma
1188P. Clinical and Immune effects patients with progressive disease treated with low dose of anti-CTLA-4, bortezomib, gemcitabine, naproxen and meloxicam.
1189P. 4SC-202 plus Anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma
ePoster1193P. Pooled data analysis of the safety and tolerability of intravenous Pelareorep in combination with chemotherapy in 500 + cancer patients
1195P. Compromised efficacy of PD-L1 blockade therapy in axenic (germ-free) mice with syngeneic tumors
1198P. Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer
1203P. Functional screening of B7H6-based chimeric antigen receptor (CAR) designs
1204P. Concurrent Immuno-radiotherapy in lung and renal cancer- a new treatment paradigm
1206P. Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small-cell lung cancer (NSCLC) preclinical models
1227P. Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC)
1230P. Modulation of Risk and Prognosis of Cutaneous Melanoma Patients by Genetic Polymorphisms on PDCD1 Gene
1232P. Investigation of AMBRA1 as a melanoma susceptibility gene
1233P. Influence of an intronic polymorphism in the MITF gene, of melanogenic pathway, in the risk and the prognosis of cutaneous melanoma
1234P. Hybrid-capture based genomic profiling identifies BRAF V600 and non-V600 alterations in melanoma samples negative by prior testing
1236P. Does melanoma or other skin cancers belong to the BRCA2 phenotype?
1237P. Resected malignant melanoma at high risk of recurrence in SEER-Medicare
1238P. Independent prognostic impact of lympho-vascular invasion in cutaneous melanoma patients with sentinel lymph node biopsy
1239P. Validating prognostic models in metastatic uveal melanoma (MUM), an International Rare Cancers Initiative
1240P. Impact of an active surveillance programme on outcome of patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): results of a single-institution experience
1241P. Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis
1242P. Neutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma.
1244P. Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
1245P. Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
1246P. Loss of USP28 drives resistance to BRAF targeted therapy in melanoma
1247P. Patterns of progression in metastatic melanoma patients treated with Braf and Mek inhibitors: an Italian Melanoma Intergroup (IMI) study
1248P. Tumor-stroma interactions as a determinant of drug resistance in BRAF-mut melanoma.
1249P. Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program.
1250P. Real-world use of ipilimumab and nivolumab monotherapy or in combination in patients with advanced melanoma: results from a retrospective chart review
1251P. Baseline neutrophil-to-lymphocyte ratio and its values monitored over time is associated with outcome of metastatic melanoma patients treated with immunotherapy
1252P. Early safety from phase 1b/3, multicenter, open-label, randomized trial of talimogene laherparepvec (T-VEC) + pembrolizumab (pembro) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): MASTERKEY-232
1254P. Tolerance and outcomes of stereotactic radiosurgery combined with anti-PD1 (pembrolizumab) for melanoma brain metastases.
1261P. mRNA capture sequencing enabled liquid biopsy screening
1262P. Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients
1263P. BRCA1 large gene rearrangements (LGRs) in Russian breast cancer patients: the development of the droplet digital PCR assay for LGR detection and the identification of recurrent exon 8 deletions
1264P. Clinical evaluation of low density array based EGFR mutation detecting kit using tissue samples and liquid biopsies
1265P. Correlation of somatic genomic alterations between tissue genomics and circulating tumor DNA (ctDNA) employing next generation sequencing (NGS) analysis in lung and gastrointestinal cancers.
1266P. Analytical and clinical validation of a next-generation sequencing-based circulating tumor DNA (ctDNA) assay assures its clinical application
1268P. Retrospective analysis of a SHIVA01 trial cohort using functional mutational analysis successfully predicted treatment outcome
1269P. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers
1270P. 3D Cultured Tumour from Patients to Predict Treatment Response
1271P. 5-ALA administration for photodynamic diagnosis of peritoneal metastases due to advanced gastric cancer: A randomised, double-blind, multicentre phase I/II study
1272P. Diagnostic performance of dedicated breast PET scanner with a ring detector
1281P. Relevance between PD-L1 and radiological invasiveness in pathological stage I lung adenocarcinoma
1284P. HOXA-related long non-coding RNAs impact prognosis in early stage NSCLC patients
1290P. DNA repair gene expression in bronchial washing fluid as new molecular tool for clinical outcome decision
1291P. Diagnosis and monitoring of Non-Small Cell Lung Cancer patients by Next Generation Sequencing and droplet digital PCR on circulating tumor DNA.
1292P. Safety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study.
1309P. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
1310P. Survival and Safety of Atezolizumab by Best Overall Response (BOR) in the Ph III NSCLC OAK Study
1312P. Prediction of survival with durvalumab in locally advanced or metastatic NSCLC using early tumor assessments
1313P. Immune-Related Adverse Events (irAEs) in Advanced NSCLC Patients Treated With Atezolizumab: Safety Population Analyses From the Ph III Study OAK
1314P. Association Between Immune-Related Adverse Events (irAE) and Atezolizumab Efficacy in Advanced NSCLC: Analyses From the Phase III Study OAK
1316P. Efficacy and Immune Activation with PEGylated human IL-10 (AM0010) in Combination with an anti-PD1 in Advanced NSCLC - Update
1317P. Multicenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: interim analysis
1319P. Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain
1324P. Practical effectiveness efficacy and safety of nivolumab for advanced non-small cell lung cancer: a retrospective multicenter analysis
1325P. Generalization and representativeness of phase III immune checkpoint inhibitor trials in NSCLC
1326P. Long-term follow-up results of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with an epitope derived from Indoleamine 2,3 Dioxygenase (IDO) in a phase I study
1328P. Association of single nucleotide polymorphisms with efficacy in nivolumab-treated NSCLC patients
1329P. Systematic inflammation and histologic grade in non small cell lung carcinoma
1331P. Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): circulating tumour (ct) DNA analysis across 3 platforms
1332P. Influence of plasma T790M mutation on clinical decision after 1st generation EGFR-TKI resistance in a Real-world study
1333P. Detectability of RET fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project : LC-SCRUM-Japan
1335P. EGFR T790M detection in TKI-naïve NSCLCs carrying sensitive EGFR mutations
ePoster1336P. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
1337P. A meta-analysis on epidemiology of ROS1 rearrangement in Asian and non-Asian population
1338P. EGFR Mutation Detection in Plasma Cell-free DNA Correlates with Clinical Outcomes in Non-Small Cell Lung Cancer
1339P. A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY).
1340P. Transcriptomic analysis of bronchoalveolar lavage cells from advanced non-small cell lung cancer identifies overexpressed immunoglobulin genes of immunosuppressive implication
1341P. Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA
1342P. Detection of epidermal growth factor receptor mutations in circulating cell-free DNA versus tumor biopsy
1343P. Efficacy and Safety of Lorlatinib in Patients (pts) With ALK+ Non-Small Cell Lung Cancer (NSCLC) Previously Treated With 2nd-Generation ALK TKIs
1344P. Brigatinib (BRG) in Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer (NSCLC): Long-term Efficacy and Safety Results From a Phase 1/2 Trial
1345P. Intracranial Efficacy of Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer (NSCLC) and Baseline CNS Metastases
1346P. CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC
1347P. Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC
1348P. Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non small cell lung cancer (NSCLC) treated with osimertinib: results from two Phase II studies
1349P. Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7
1350P. Phase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC)
1352P. Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer
1353P. CNS response to osimertinib in Asian-Pacific patients (pts) with T790M-positive advanced NSCLC: data from an open-label Phase II trial (AURA17)
1354P. Osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: updated Phase II study results including progression-free survival (PFS)
1355P. Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program
1356P. Octogenarians with EGFR-mutated non-small cell lung Cancer (NSCLC) treated by Tyrosine Kinase Inhibitor (TKI): a multicentric real world study assessing tolerance and efficacy. OCTOMUT study GFPC 07-15.
1357P. Prospective evaluation of the relationship between erlotinib concentration and efficacy in patients with non-small cell lung cancer harboring EGFR-activating mutations.
1358P. First-In-Human Phase I Study of PF-06747775, a Third Generation Mutant Selective EGFR Tyrosine Kinase Inhibitor (TKI) in Metastatic EGFR Mutant NSCLC after Progression on a First-Line EGFR TKI
1359P. Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network
1360P. Phase II Trial of AZD9291 in Second Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA (LiquidLung-O-Cohort 2)
1362P. Safety and clinical activity of DS-6051b, a ROS1/NTRK inhibitor, in Japanese patients with NSCLC harboring ROS1 fusion gene
1363P. Efficacy and Safety of Abemaciclib Combined with either LY3023414 or Pembrolizumab in Stage IV NSCLC
1364P. Final Clinical Results from SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Stage IIIb/IV Nonsquamous Non Small Cell Lung Cancer
1365P. Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies.
1366P. Effect of nab-paclitaxel/carboplatin (nab-P/C) induction therapy on quality of life (QoL) of patients with squamous (SCC) non-small cell lung cancer (NSCLC) (ABOUND.sqm)
1367P. Quality of Life (QoL) in Elderly NSCLC Patients (pts) Treated with nab-Paclitaxel/Carboplatin (nab-P/C) in the ABOUND.70+ Trial
1368P. Phase I/II trial of weekly nab-Paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)
1369P. nab-Paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): interim safety results from ABOUND.sqm
1370P. Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC - results from prospective German TLK cohort study
1371P. Diagnostic and therapeutic strategies for elderly patients with advanced Non-Small cell lung cancer (NSCLC): results from an EORTC pan-european survey
1372P. Diversity of brain metastasis (BM) management in non-small cell lung cancer (NSCLC) in Europe (EU): Results of the Young Investigators European Organisation for Research and Treatment of Cancer Lung Cancer Group (YI EORTC LCG) survey
1373P. Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study
1374P. Characteristics and Prognostic Impact of Advanced Non-Small-Cell Lung Cancer Patients Who Were Ineligible for Clinical Trials
1375P. Treatment paradigm shift in NSCLC: patient data analysis from 2005 to 2016
1390P. Efficacy of Anamorelin in Advanced Non-small Cell Lung Cancer (NSCLC) Patients with Anorexia/Cachexia and Modified Glasgow Prognostic Score (mGPS) of 2: Pooled Analysis of Two Phase 3 Trials
1391P. Prognostic Nutritional Index (PNI) for cost effective utilisation of newer, expensive radiation technology for palliative treatment of all cancer patients with limited life expectancy.
1392P. Characterization of Cachectic Patients with Non-small Cell Lung Cancer (NSCLC) According to Their Modified Glasgow Prognostic Score (mGPS)
1393P. Chemotherapy in advanced cancer patients with poor performance status (PS) initiated in an integrated oncology and palliative care (PC) setting: an observational comparative study
1395P. Specialized ambulatory palliative care: (SAPV) 5-year results of a multi-professional care model by HomeCare linker Niederrhein gGmbH (HC) in the Lower Rhine region
1396P. Increasing palliative interventions at the end of life: patterns in metastatic colorectal cancer (mCRC)
1397P. Chronic pleural effusion in malignancy: a single center's ten years expertise with indwelling pleural catheters
1398P. Aggressiveness of care at the end of life in children with cancer - a nationwide cohort study
1403P. Community-based Lung Cancer Screening of High-risk Population with Low-dose Computed Tomography in China
1404P. Colon Cancer Screening by Fecal Immunochemical Testing in Iran
1405P. Diagnostic analysis of patients referred from general practitioner with serious non-organ-specific symptoms and signs of cancer: a retrospective cohort study
1408P. A study of body fat composition, derived from DXA-scans, in association with cancer incidence in postmenopausal women.
1409P. Cervical cancer screening in France: recent change in behaviors
1410P. The role of tumour marker testing in earlier diagnosis of cancer
1411P. Genetic counseling, screening and risk reducing practices in patients with BRCA mutations
1412P. Ischemic stroke as cancer predecessor and associated predictors
1413P. Gastric cancer detected after Helicobacter pylori eradication at one private screening center in Japan
1415P. NGS and Sanger screening for BRCA1/BRCA2, CHEK2 and TP53 in argentinian high-risk breast/ovarian cancer families and bioinformatic studies: initial results
ePoster1416P. The change in self-perceived characteristics of health and lifestyle due to colorectal cancer screening invitation and attendance
1417P. Multi-gene panels: new clinical experience in hereditary breast and ovarian cancer
1418P. Clinical features and outcomes of reversible posterior encephalopathy syndrome following bevacizumab treatment
1419P. Deliberative democracy and cancer screening. The use of citizens' s juries in health policy decision-making
1421P. Recommended cancer screening and vulnerable populations: results from the EDIFICE 5 survey
1423P. Loneliness and Cognitive dysfunction in Elderly Cancer Patients
1424P. The study of emotional distress in oncology patients
1425P. Risk of mood disorders in long-term cancer survivors: a population-based cohort study
1426P. What Oncologists should know about the screening of psychological distress: one example of pilot study in Ancona
1427P. Biopsychosocial factors underlying older patients treated for an incurable cancer in a two-tiered health care system in Brazil
1428P. Family-associated factors influence the postoperative prognosis in patients with non-small cell lung cancer
1430P. Sexual Functioning and Quality of Life in Egyptian Premenopausal Patients Receiving Treatment for Breast Cancer
1431P. Primary results of a study to evaluate a decision aid for women offered neoadjuvant systemic therapy for breast cancer
1433P. Burnout syndrome: what impact on clinical research?
1445P. Inclusion of older patients with colorectal cancer in clinical trials: the SAGE prospective multicenter cohort study
1446P. Risk of second primary cancers and competing mortality in survivors of adult-onset cancer: changing pattern over three decades
1447P. Reporting of randomized trials in common cancers in the lay media
1448P. Effect of rural residence (RD) and distance travel to the cancer center (DTC) on neoadjuvant chemoradiation (NCRT) in localized rectal cancer.
1450P. European survey of 907 people with cancer about the importance of nutrition
1451P. Breast cancer-specific survival in young women <40 years with node-negative luminal breast cancer treated based on tumor gene expression
1453P. Tobacco exposure and adverse pathological features in oral cancer : does age impact survival ?
1455P. Initiation of Systemic Anti-Cancer Treatment in the Inpatient Setting in a Tertiary Hospital in London
1456P. Young-age onset colorectal cancer: analysis of incidence, clinical features and outcomes
1457P. Improved provision of written information on metastatic spinal cord compression to at-risk cancer patients at a tertiary referral centre
1459P. Cancer incidence and mortality trends in Crete, Greece during the last two decades (1992-2013): Results from the cancer registry of Crete.
1460P. Robotic anticancer drug compounding assist system for the preparation of injectable antineoplastic drugs
1461P. Monitoring of contamination with cytostatics in pharmacies and hospitals in the Czech Republic
1462P. "New treatments in Oncology: clinical practice regarding the management of Adverse Events (AEs)": results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO).
1464P. Ukrainian Association for helping Patients With Lymphoproliferative Diseases: Patients support care program
1465P. Do Oncology Patients Understand Clinical Trials? A Nationwide Study By Cancer Trials Ireland
1466P. Feasibility and barriers to optimal oncological treatment in solid organ transplant patients with de novo cancer
1467P. Generating patient reported outcome norms for an EU cancer population using real world data (FACT-G)
1469P. Survival Patterns for Different Types of Cancers in the United States (1973-2012)
1470P. Decisions And Supports Around Clinical Trial Participation: A National Study By Cancer Trials Ireland
1471P. Academic Clinical Research: enough players to get out there?
1472P. Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients
1485P. Localized undifferentiated endometrial sarcomas (LUES): results of a French Sarcoma Group (FSG) retrospective series of 39 patients (pts)
1486P. An epidemiological insight into epithelioid sarcoma (ES): the open issue of distal-type (DES) versus proximal-type (PES)
1487P. Natural history of Alveolar Soft Part Sarcoma (ASPS): impact of Brain Metastases and Role of Anti-Angiogenic Therapies (AAT)
1488P. Treatment patterns, clinical outcomes and prognostic factors of visceral angiosarcoma (V-AS): A report from the Asian Sarcoma Consortium (ASC)
1489P. High dose loco-regional chemotherapy for locally advanced angiosarcoma - a multicenter study
1490P. Primary cardiac sarcoma (PCS): A Multi-national Retrospective Review of Clinical Experience
1491P. Primary cardiac Sarcoma: A retrospective study in two Korean tertiary centers.
1492P. The differences in recurrence and survival of extremity liposarcoma subtypes
1493P. The Sarcoma Policy Checklist - focusing policy efforts on sarcoma
1494P. Dermatofibrosarcoma Protuberans might not benefit from Postoperative Radiotherapy after Local Resection with Negative Margin
1495P. Low-dose chemotherapy with methotrexate and vinblastine for desmoid tumors: a single institution experience
1496P. EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: clinical profile and response to systemic therapy
1497P. Efficacy and Safety of Patients Treated Long-Term with Trabectedin (T) on the Expanded Access Program: A Retrospective Analysis
1498P. Efficacy and Safety of Trabectedin in an Elderly Patient Subgroup (?65 years) with Advanced Leiomyosarcoma (LMS) or Liposarcoma (LPS) from the Expanded Access Program (EAP)
1499P. The routine real-life use of trabectedin (T) in patients with advanced soft tissue sarcoma (STS) across Europe: an analysis of overall vs. per country results from Y-IMAGE study
1501P. Safety and efficacy of pazopanib (PAZ) in advanced soft tissue carcinoma (aSTS) by prior lines of therapy, age, and dose modifications: PALETTE subgroup analyses
1502P. Evolution in Neutrophil-to-lymphocyte ratio (NLR) among advanced Soft Tissue Sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials
1503P. Benefit of the use of tyrosine kinase inhibitors (TKIs) in patients (pts) with METAstatic Soft Tissue SARComa (STS) in a Real-Life Setting: an ancillary analysis of the METASARC Study
1504P. Response to apatinib in advanced alveolar soft part sarcoma
1505P. Analysis of expression of immunomodulation factors in alveolar soft-part sarcoma: a retrospective study from the Spanish Group for Research on Sarcoma (GEIS)
1507P. Pembrolizumab (PEM) in patients with advanced/metastatic bone sarcoma (BS) or soft tissue sarcoma (STS): named patient use by the Medical University of Vienna
1509P. Characteristics and prognosis of gastrointestinal stromal tumor in the pre-imatinib era: an analysis based on the Kinki GIST registry in Japan
1510P. Early response evaluation by 18F-FDG-PET influences management in gastrointestinal stromal tumor patients treated with neo-adjuvant intent
1512P. Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (> 5 years) to frontline imatinib (IM): a case-control study from GEIS
1513P. Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) receiving placebo or regorafenib in the phase 3 GRID trial
1515P. LncRNA H19, HOTAIR and MALAT1 as prognostic molecular biomarkers in GIST.
1516P. Predictive factors of response to Sunitinib in metastatic Gastrointestinal Stromal Tumors (mGISTs): a retrospective analysis.
1517P. Analysis of PD-L1 Expression in Patients with Gastrointestinal Stromal Tumors
1519P. Primary pleomorphic sarcoma (PS) and leiomyosarcoma (LMS) of bone: retrospective analysis of an original series
151PD. Efficacy and Safety of Biosimilar ABP 980 Compared With Trastuzumab in HER2 Positive Early Breast Cancer
1520P. Development of a new promising rescue agent for high dose methotrexate (HDMTX) treatment in osteosarcoma - a safety and dose finding study
1523P. Efficacy of second line treatment with etoposide and ifosfamide in adult patients with advanced Ewing Sarcoma Family Tumors.
152PD. Double-blind, Randomized Phase III Study to Compare the Efficacy and Safety of Trastuzumab and its Biosimilar Candidate CT-P6 in HER2 Positive Early Breast Cancer (EBC)
1532P. The role of thoracic radiotherapy on peripheral lymphocyte subsets in patients with limited-stage small cell lung cancer
1534P. Antidepressants simulate Enriched environment enhance platinum chemosensitivity of small cell lung cancer
153PD. One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment
154PD. A randomized, double-blind study of PF-05280014 (a potential biosimilar) vs trastuzumab, both given with docetaxel (D) and carboplatin (C), as neoadjuvant treatment for operable human epidermal growth factor receptor 2-positive (HER2+) breast cancer
1550P. Primary prevention of nausea and vomiting induced by moderately emetogenic chemotherapies: findings from the French CONVINCE-ME survey
1551P. Risk factors of chemotherapy-induced nausea and vomiting during cisplatin regimen in antiemetic triplet regimen including palonosetron or granisetron: TRIPLE study (Phaselll )
1552P. Evaluation of Antiemetic Practices for Prevention of Chemotherapy-induced Nausea and Vomiting (CINV): Results of a European Oncology Nurse Survey
1553P. A pooled analysis evaluating the combination antiemetic therapy on chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk
1554P. Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis.
1555P. Pharmacokinetic (PK) study of a single oral dose of NEPA in Chinese healthy volunteers
1556P. Iron deficiency anaemia in oncology: an epidemiological prospective study.
1557P. Nutritional risk as a predictor of short-term outcomes in a prospective cohort of elderly patients with cancer
1558P. A patient-centered approach to the re-development of supportive care services for oncology adolescent and young adult (AYA) patients (pt(s)) across McGill University hospitals (Rossy Cancer Network-RCN)
1559P. Multidimensional telemonitoring of cancer patients (pts) receiving chronomodulated (chrono) Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O; chronoIFLO4) combination at home
155PD. Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
ePoster1560P. A pilot study to evaluate the feasibility, usability, and perceived satisfaction with eCO (eCediranib-Olaparib), a mobile application for side effect monitoring and reporting, in women with recurrent ovarian cancer.
1561P. Study of the satisfaction level of an education program for cancer patients
1562P. Factors influencing the use of thromboprophylaxis in cancer outpatients: CAT AXIS, a case-vignette study on clinical practice.
1563P. Literature review of TPOR Agonists for CIT
ePoster1564P. Random optimization Interactive System based on Kernel learning (RISK) for venous thromboembolism risk assessment in chemotherapy-treated cancer patients
1565P. Association between systemic inflammation and symptoms in advanced cancer patients
1566P. Outcomes of Patients with Malignancy Admitted to the Intensive Care Units (ICU): a Prospective Study
1568P. Management of Thrombosis in cancer patients in Greece
1569P. Incidence and outcome of Incidental Pulmonary Embolism (IPE) in oncology patients with current macroscopic disease